Laimei Pharmaceutical Co., Ltd.: The controlling shareholder intends to transfer 23.43% of the shares by agreement. Laimei Pharmaceutical announced that Zhongheng Group, the controlling shareholder, intends to transfer 247 million shares of the company's unrestricted tradable A shares by public solicitation of the transferee, accounting for 23.43% of the company's total share capital, and the transfer price is not less than 4.42 yuan/share. If the share transfer is completed, the controlling shareholder and actual controller of the company may change.Institution: The Swiss National Bank does not need to cut interest rates sharply again. Melanie Debono, a macroeconomic analyst at Pantheon, wrote in a report that the Swiss National Bank does not need to cut borrowing costs sharply again. Earlier, the Swiss National Bank unexpectedly cut interest rates by 50 basis points. Most analysts had expected a more cautious rate cut of 25 basis points. Debono said that there may be further relaxation after this move, but only a little. Pantheon Macroeconomics predicts that the Swiss National Bank will cut interest rates by 25 basis points again in March next year.
US President-elect Trump: Opposing Ukrainian armed forces to attack Russia with US long-range missiles has further escalated the conflict.Huichuan technology: the company has started to apply AI technology in the field of machine vision. Huichuan technology said at the performance briefing that in the field of AI: the company has started to apply AI technology in the field of machine vision, and the exploration in other fields will be carried out according to customer needs and industrial development. In the field of humanoid robots: the company is currently led by the product competitiveness center, and multi-departments cooperate to develop core components such as motors, drivers and actuator modules. The spin-off and listing of the company's subsidiary, United Power, is progressing steadily and is still in the stage of listing counseling.Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today. Tongfu Microelectronics traded 2.24 million shares at a discount of 60.0768 million yuan today, accounting for 3.32% of the total turnover of the day, and the transaction price was 26.82 yuan, which was 9.97% lower than the market closing price of 29.79 yuan.
The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.Australia's ASX 200 index narrowed to 0.1%, and the Australian dollar increased. The just released Australian employment data was better than expected.Truck manufacturer Paccar recalled more than 220,000 American cars due to electronic system problems. The National Highway Traffic Safety Administration (NHTSA) said on Thursday that truck manufacturer Paccar recalled 220,972 cars in the United States because there was a problem with the electronic control unit (ECU), which might affect the systems related to braking and stability control. NHTSA said that the recalled vehicles included some Peterbilt and Kenworth cars produced in 2021-2025.